Legend Capital Portfolio: Nuclei, the World’s First RISC-V CPU IP Vendor, Accomplishes ISO 26262 ASIL-D Product Certificate

Legend Capital’s portfolio company, Nuclei System Technology, a leading RISC-V CPU IP vendor in China, announces that NA900 has been certified to be compliant with ASIL D requirements of ISO 26262 standards for both systematic fault and random hardware fault. NA900 becomes the world’s first RISC-V CPU IP achieving ISO 26262 ASIL D product certificate.
The NA900 processor has been developed as a hardware SEooC according to ISO 26262-10. The development meets the applicable ASIL D design specification, implementation and verification requirements of ISO 26262 parts 4,5,7,8,9 as guided by ISO 26262-10, and the functional safety management requirements per ISO 26262-2. According to the official assessment report, NA900 meets both systematic capability and hardware safety integrity with ASIL D. Nuclei is the first RISC-V CPU IP vendor in the world to get ASIL D product certificate.

NA900 is a configurable CPU core features a 9-stage, dual-issue pipeline supporting RISC-V RV32IMACFDPB ISA.

NA300D has been assessed according to ISO 26262-5:2018 with SGS and gets ASIL D Ready certificate for hardware safety integrity. According to SGS assessment report, NA300D meets the architectural metrics SPFM and LFM with ASIL D target values.

NA300 is a configurable CPU core that features a 3-stage, single-issue pipeline supporting RISC-V RV32IMACFDPB/Zc ISA.

“It’s a great honor for Nuclei to obtain the world’s first ISO 26262 ASIL D product certificate of RISC-V CPU IP, which is a huge achievement of the team. This is a significant milestone not only for Nuclei, but also for the entire RISC-V ecosystem booming in the automotive industry. Together with our partners, Nuclei will continue expanding FUSA compliant product portfolio in the near future.” said Jianying Peng, CEO of Nuclei.

About Legend Capital
Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.

It currently manages USD and RMB funds of over US$10 billion in commitments and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.

Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital ( https://www.linkedin.com/company/legend-capital ).

About Nuclei System Technology
Established in 2018, Nuclei System Technology is a leading RISC-V CPU IP vendor in China. Nuclei dedicates to developing high-performance/low-power processors and their associated SoC platforms to serve the rapidly growing computing applications worldwide.

Starting from scratch, Nuclei provides a full series of processors that can meet various markets and applications, including RISC-V 32-bit (N/U classes) & 64-bit architecture(NX/UX classes), security (NS class) & automotive (NA class), etc. As of today, more than 150 customers have officially licensed Nuclei’s processor IPs. covering MCU, AIoT, 5G communication, industrial control, artificial intelligence, automotive electronics, storage, Ethernet, etc.
https://nucleisys.com

The article is distributed by Ever Bloom (HK) Communications Consultants Group Limited on behalf of Legend Capital.

For further information, please contact:
Ms. Orianna Ou / Ms. Arina He
Tel: +852 3468 8171
Email: legendcapital.list@everbloom.com.cn


Topic: Press release summary

Backed by Legend Capital, the Chinese Pet Food Industry Leader Gambol Pet Goes Public Successfully

On August 16, Legend Capital’s portfolio company, Gambol Pet (301498.SZ), was successfully listed on the ChiNext Market of the Shenzhen Stock Exchange. Gambol Pet plans to issue 40,004,500 shares at an offering price of RMB39.99 per share, with an estimated total fundraising of approximately RMB1.6 billion.

Engaged in the R&D, production and sales of pet food and providing multi-series products mainly for dogs and cats, Gambol Pet was founded in 2006 and is a leading pet food company in China. The company started with overseas OEM/ODM businesses and has gradually become a recognized supplier for international enterprises such as Walmart and Spectrum Brands. With the rapid growth of the pet food market in China, Gambol Pet has systematically expanded its presence in the Chinese market since 2013 and established its own brand, Myfoodie, which achieved full-category coverage in pet food, including pet staple food, snacks and health care products.

As one of the leading companies in the pet food industry, Gambol Pet adheres to the concept of “Global Vision, Continuous Innovation” and is committed to producing nutritious and healthy pet food that consumers need. Through its reliable product quality, continuous innovation and efficient sales network, the company made the best of the opportunity of the rapid expansion of the pet food demand in China and has formed a core lineup of proprietary brands with Myfoodie at the center.

Legend Capital invested in Gambol Pet in 2019 and 2020 and helped the company transform from an export-oriented OEM enterprise to a leading pet food enterprise in China driven by its own brand business. After the investment, Legend Capital provided value-added services to the company in various dimensions to support its business at home and abroad, including supply chain resource introduction, business sales channel connection, financial and legal compliance, and talent introduction.

QIN Hua, Chairman and CEO of Gambol Pet, said: “Gambol Pet will take the listing as an opportunity to firmly grasp the strategic window of the rapid development of the pet industry in China. We will adapt to the changes and dynamic trends in pet culture, consumer upgrades, and consumption concepts and continue increasing our products’ market share in domestic and overseas markets. Simultaneously, by continuing to accelerate our global expansion and build our global advantages in technologies, talents, markets, and supply chains, we will keep moving forward and strive to become a highly innovative international enterprise with substantial growth, as well as a leading player in the global pet food industry.”

Raymond CHEN, Co-Chief Investment Officer of Legend Capital, said: “With the continuous improvement of people’s living standards, more and more people are getting emotionally attached to pets. The pet industry in China is in its early stages and enjoys broad prospects for future development. Gambol Pet adheres to continuous innovation and emphasizes proprietary brands. Through independent R&D and product innovation, it has formed its core brand, Myfoodie, which surpassed many imported brands and helped Gambol Pet consolidate its leading position in the pet food industry. Mr. QIN Hua, Chairman of the company, is an outstanding entrepreneur with both local experience and a global vision, and we are proud of the team for achieving this remarkable achievement. Congratulations to Gambol Pet on its successful listing.”

About Legend Capital

Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.

It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.

Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital ( https://www.linkedin.com/company/legend-capital ).

The article is distributed by Ever Bloom (HK) Communications Consultants Group Limited on behalf of Legend Capital.

For further information, please contact:
Ms. Orianna Ou / Ms. Arina He
Tel: +852 3468 8171
Email: legendcapital.list@everbloom.com.cn


Topic: Press release summary

One More IPO of Legend Capital: Medical Device Supply Chain Service Provider GKHT Medical Goes Public Successfully

On July 12, Legend Capital’s portfolio company, GKHT Medical Technology Co., Ltd. (“GKHT Medical”; Stock Code: 301370.SZ), was successfully listed on the ChiNext Market of the Shenzhen Stock Exchange.

GKHT Medical is a leading comprehensive digital supply chain service provider for medical devices in China. Focusing on the field of medical devices, the company specializes in providing customized supply chain solutions to manufacturing enterprises, distributors/dealers, and medical institutions based on its entire supply chain service-covered platform for every medical device product from original manufacturers to operating rooms.

Starting with high-value medical consumables, GKHT Medical has innovatively created a brand-new business model of the “one-stop distribution platform + hospital-end service platform”, enabling the company to provide the industry with comprehensive digital supply chain services from original manufacturers to operating rooms through intensively integrating key elements such as funds, warehousing, logistics, and circulation process information.

As one of the company’s earliest investors, Legend Capital participated in GKHT Medical’s fundraising rounds in 2016 and 2019 and has kept helping enhance the company’s management and operational capabilities and connect upstream and downstream customer resources since the investments. Over the seven years of investment cooperation, GKHT Medical’s revenue has increased by more than 600%, and it has grown into a tier-one company in the field of high-value consumables for medical devices.

Joe ZHOU, Managing Director of Legend Capital, said: “GKHT Medical has an aspiring and dedicated team whose members have extensive experience in business operations and marketing and jointly drive pragmatic progress through the bonding of each other’s talents. The high-value medical consumables market in China is worth over RMB100 billion, but most supply chain links, such as distribution, are still dominated by traditional agency models. The market is still open to be explored by disruptive innovators, and we believe that GKHT Medical will stand out in the future and continue to support innovation in the field of medical devices.”

“It is believed that the listing will help GKHT Medical to further strengthen its cooperation with upstream and downstream partners, expand the coverage of its direct sales business to more terminal medical institutions, enhance operational funding, and improve its information systems and logistics warehousing system. With improved comprehensive service support capabilities and risk control capabilities, the company is well prepared to meet the changing needs of customers in different markets. At the same time, by deepening the links between the upstream and downstream of the industrial chain and expanding the supply chain business, GKHT Medical is capable of providing customers with digital supply chain services covering high-value consumables, low-value consumables, IVD, and equipment in the medical devices field. The company has established a channel of “manufacturers-GKHT Medical-hospitals” to continuously strengthen its core competitiveness as a comprehensive digital supply chain service provider for medical devices.” Joe Zhou added.

At present, GKHT Medical has provided professional services for more than 100 leading original manufacturers of medical devices and more than 4,000 hospitals worldwide, and it has achieved high-quality and scale development with the capability of delivering to more than 80% of Chinese tertiary hospitals within 2 hours.

Legend Capital has long been paying attention to the investment in the field of medical devices and diagnostics with a focus on three major themes: first, major diseases, especially the unmet clinical needs of chronic diseases; second, the first and uniqueness in technology, which enables a company to become or have the potential to become a leading player in subdivided industries; the third is the “device +” investment opportunities brought by the integration of medical devices and interdisciplinary technologies such as AI, IoT and Big Data. At present, Legend Capital has invested in numerous leading companies in the subdivided industries, including GKHT Medical (301370.SZ), Careray Digital Medical Technology (688607.SH), Axonics (AXNX), New Horizon Health (06606.HK), Wuhan Easy Diagnosis Biomedicine (002932.SZ), Berry Genomics (000710.SZ), Aohua Photoelectricity Endoscope (688212.SH), Chemclin Diagnostics (688468.SH), Bio-heart Biological (02185.HK), STAR Sports Medicine, ET Healthcare, Hailai Xinchuang Medical Technology, and Dearer Medical.

Legend Capital has been actively investing in the healthcare industry since 2007 and has built a distinctive and valuable healthcare ecosystem. The company has created a powerful investment base on the strength of many pillar enterprises it invested in multiple subdivided healthcare industries. In response to changes in the external environment, Legend Capital has proposed a new “healthcare ecosystem +” strategy aiming at the new development pattern of the healthcare industry. By taking capital as the link and focusing on “innovation” and “ecosystems”, Legend Capital intends to build a more extensive ecosystem that connects resources from various sectors, including the industry, academia, and society, to accelerate the transformation of R&D results, promote industrial upgrading, and achieve high-quality development.

About Legend Capital

Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.

It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.

Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital ( https://www.linkedin.com/company/legend-capital ).


Topic: Press release summary

What to know before you play the Legend of Zelda: Tears of the Kingdom!

WEBWIRE

The wait is overthe Legend of Zelda: Tears of the Kingdom game is finally here! Theres a lot to discover, and we want you to put your best boot forward when you set out in Hyrule.

Lets start with a few important tips before you start playing. But dont worry, well stay away from any spoilers. Think of this article as a way to help get in the right mindset before playing.

Oh! And well be bringing you more tips articles in the coming weeks, so be sure to keep an eye on the news feed.

Tip 1: Unlearn what youve learned

Yeah, this may sound like something youd be told from a martial arts master, but hear us out. Whether youve played hundreds of hours of The Legend of Zelda: Breath of the Wild or are brand new to the series, your experience level doesnt really matter when it comes to this game.

While things youve done in previous games may still work, you have a wide variety of options in this sequel. Sure, you can still fight enemies with a stick or you can fuse a boulder to your stick and jump on springboards to bonk enemies on the head. Sure, you can climb your way out of a hole or you can use the Ascend ability to travel through the ceiling and get where you need to go.

Tip 2: Try everything

This game encourages you to try new things throughout. From traveling around Hyrule to solving puzzles, there are multiple ways to overcome problems you run into. The joy comes from trying out crazy ideas that end up working.

Oh, and if something isnt working out the way you want, take a moment and try something else. Some players find joy in attempting a difficult jump over and over. Others would rather build a bridge. Experimentation is the heart of this gameeven if a situation doesnt go as expected, you may stumble upon something that will help you later.

Tip 3: Get some perspective

When you enter a new area, find a tall vantage point and scope out your surroundings. Youll find all sorts of stuffenemies, chests, materials, objects or terrain that will help in fights, and more. Believe us, it will be easier to do this before enemies spot you. Speaking of

Tip 4: Prepare for fights beforehand

Look, you dont have to do thiswere (sometimes) fond of charging into the middle of things while screaming and wildly waving our arms too. But if you want to use the Fuse ability to make strong weapons or Ultrahand to build a makeshift missile turret, you may want to do that before Bokoblins are trying to smack you around. A little prep time can go a long way.

Tip 5: Use your words

This wont work on enemies (at least the ones weve tried) but try talking to the more peaceful characters out there! In particular, characters called Constructs may give you helpful tips about the area.

Tip 6: Play it your way

OK, this is probably the most important tip. Sure, Link is the character in the game, but remember that you are the hero here. You are saving Hyrule. And you can do it how you want to! Play around with everything you get your hands on, because theres room for massive creativity (and shenanigans) in this game.

With that said, dont worry about not being creative enough. Everyone is creative on some level, and a part of creativity is giving yourself permission to try new things. We all play in different waysmessy ways, elaborate ways, unexpected ways, and silly ways that have no purpose other than to see what happens. Dont worry about playing the game the right way because its up to you how you want to approach obstacles. If something works in the end, its a success. If it doesnt, did you at least get a chuckle out of it?

Tip 7: Share the knowledge

And finally, creativity comes alive when you share what you know and get inspired by others. Talk to your friends to see what theyve tried. Maybe find out what other people have done. You may be surprised what ends up inspiring you!

Alrighty, thats all for now. Be on the lookout for our next tips article which will cover the four new abilitiesFuse, Ultrahand, Ascend, and Recall. You can also buy the game using the link below.

Have fun out there!

The Legend of Zelda: Tears of the KingdomRegular Price:$69.99Nintendo Switch

Learn more

Led by Legend Capital, Macrolux Completes Nearly CNY100 million Series A Round

Shenzhen Macrolux Medical Technology Co., Ltd. (hereinafter referred to as “Macrolux”) recently announced the completion of its Series A round by securing nearly CNY100 million, which is led by Legend Capital.
Founded in October 2020 and headquartered in Shenzhen, Macrolux is a medical technology company focusing on innovative solutions for endoscopic interventional diagnosis and treatment. Macrolux’s founding team is formed from experts from leading medical device companies in China and has more than a decade of experience in product development, global marketing and the production management of endoscopes and minimally invasive surgical devices. With a vision of detecting diseases earlier and offering patients better treatments, Macrolux is committed to providing the world with endoscopic interventional diagnosis and treatment solutions covering departments including urology, respiration, and digestion by leveraging its engine for innovation-driven development.

Regarding this fundraising round, ZHANG Weiqiang, General Manager of Macrolux, said: “I’d like to extend my sincere gratitude to all the investors for their trust in Macrolux. Disposable electronic endoscopes are an early market experiencing rapid growth. With years of concentrating on the product development and technological innovation of disposable endoscopes, Macrolux has formed strong competitiveness in many aspects and aims to introduce solutions to the world that better meet customer needs relying on our ten more years of technology accumulation in the industry.”

Joe ZHOU, Managing Director of Legend Capital, said: “Legend Capital has focused on endoscopic diagnosis and treatment, which is a development direction of minimally invasive medical treatment. It is noticed that disposable endoscopes have solved the sore points of traditional medical devices in multiple application scenarios and have begun to penetrate rapidly in recent years. All the functional teams of Macrolux are experienced and have worked in a balanced way for a long time and shared complete commercialization experience from scratch to impressive performance. We are honored to cooperate with the team and look forward to the company’s innovative series of products accelerating penetration into clinical applications to benefit patients globally.”

Legend Capital has long been paying attention to the investment in the field of medical devices and diagnostics with a focus on three major themes: first, major diseases, especially the unmet clinical needs of chronic diseases; second, the first and uniqueness in technology, which enables a company to become or have the potential to become a leading player in subdivided industries; the third is the “device +” investment opportunities brought by the integration of medical devices and interdisciplinary technologies such as AI, IoT and Big Data.

At present, Legend Capital has invested in numerous leading companies in the subdivided industries, including Careray Digital Medical Technology (688607.SH), Axonics (AXNX), New Horizon Health (06606.HK), Wuhan Easy Diagnosis Biomedicine (002932.SZ), Berry Genomics (000710.SZ), Aohua Photoelectricity Endoscope (688212.SH), Chemclin Diagnostics (688468.SH), Bio-heart Biological (02185.HK), STAR Sports Medicine, ET Healthcare, GKHT Medical Technology, Hailai Xinchuang Medical Technology, Yeasen Biotechnology, and Dearer Medical.

About Legend Capital

Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.

It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.

Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital).


Topic: Press release summary